APO Research
Talk to an analyst

APO RESEARCH · REPORT

Prostate Cancer Drugs

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Prostate Cancer Drugs Market Outlook and Growth Opportunities 2026

20 December 2025216 pages

Choose your research edition.

Industry ResearchProstate Cancer Drugs Industry Research Report 2026144 pages · $2,950 USDIndustry Growth & TrendsGlobal Prostate Cancer Drugs Industry Growth and Trends Forecast to 2032126 pages · $3,450 USDMarket StructureGlobal Prostate Cancer Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032196 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Prostate Cancer Drugs Market Outlook and Growth Opportunities 2026216 pages · $4,250 USDMarket Analysis & ForecastGlobal Prostate Cancer Drugs Market Analysis and Forecast 2026-2032217 pages · $4,950 USD

Market perspective

The global Prostate Cancer Drugs market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Prostate Cancer Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Prostate Cancer Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Prostate Cancer Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Prostate Cancer Drugs market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Prostate Cancer Drugs market include Takeda Pharmaceuticals, Teva Pharmaceutical, Sanofi, Johnson & Johnson, Novartis, Merck Group, GlaxoSmithKline, Amgen and AbbVie, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Prostate Cancer Drugs market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Prostate Cancer Drugs and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Prostate Cancer Drugs sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Prostate Cancer Drugs market size, projected growth trends, production technologies, key applications, and end-use industries.

Prostate Cancer Drugs Segment by Company

Takeda Pharmaceuticals

Teva Pharmaceutical

Sanofi

Johnson & Johnson

Novartis

Merck Group

GlaxoSmithKline

Amgen

AbbVie

Tokai Pharmaceuticals

Spectrum Pharmaceuticals

Northwest Biotherapeutics

Janssen Pharmaceuticals

Foresee Pharmaceuticals

Ferring Pharmaceutical

Endo Pharmaceuticals

Boehringer Ingelheim

BMS

Bayer HealthCare

Astra Zeneca

Astellas Pharma

Prostate Cancer Drugs Segment by Type

Targeted Therapy

Chemotherapy

Hormonal Therapy

Immunotherapy

Prostate Cancer Drugs Segment by Application

Clinics

Hospitals

Others

Prostate Cancer Drugs Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Nordic Countries

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Colombia

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global Prostate Cancer Drugs status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Prostate Cancer Drugs market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Prostate Cancer Drugs significant trends, drivers, influence factors in global and regions.

6. To analyze Prostate Cancer Drugs competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Prostate Cancer Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Prostate Cancer Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Prostate Cancer Drugs.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Prostate Cancer Drugs market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Prostate Cancer Drugs industry.

Chapter 3: Detailed analysis of Prostate Cancer Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Prostate Cancer Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Prostate Cancer Drugs in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Prostate Cancer Drugs Industry Trends Table 2. Prostate Cancer Drugs Industry Drivers Table 3. Prostate Cancer Drugs Industry Opportunities and Challenges Table 4. Prostate Cancer Drugs Industry Restraints Table 5. Global Prostate Cancer Drugs Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Prostate Cancer Drugs Revenue Share by Company (2021-2026) Table 7. Global Prostate Cancer Drugs Sales Volume by Company (K Tons) & (2021-2026) Table 8. Global Prostate Cancer Drugs Sales Volume Share by Company (2021-2026) Table 9. Global Prostate Cancer Drugs Average Price (US$/Ton) of Company (2021-2026) Table 10. Global Prostate Cancer Drugs Company Ranking, (2024-2026) & (USD Million) Table 11. Global Prostate Cancer Drugs Key Company Manufacturing Base & Headquarters Table 12. Global Prostate Cancer Drugs Company, Product Type & Application Table 13. Global Prostate Cancer Drugs Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Prostate Cancer Drugs by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Targeted Therapy Table 18. Significant Companies of Chemotherapy Table 19. Significant Companies of Hormonal Therapy Table 20. Significant Companies of Immunotherapy Table 21. Global Prostate Cancer Drugs Sales Volume by Type 2021 VS 2025 VS 2032 (K Tons) Table 22. Global Prostate Cancer Drugs Sales Volume by Type (2021-2026) & (K Tons) Table 23. Global Prostate Cancer Drugs Sales Volume by Type (2027-2032) & (K Tons) Table 24. Global Prostate Cancer Drugs Sales Volume Share by Type (2021-2026) Table 25. Global Prostate Cancer Drugs Sales Volume Share by Type (2027-2032) Table 26. Global Prostate Cancer Drugs Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 27. Global Prostate Cancer Drugs Sales Value by Type (2021-2026) & (US$ Million) Table 28. Global Prostate Cancer Drugs Sales Value by Type (2027-2032) & (US$ Million) Table 29. Global Prostate Cancer Drugs Sales Value Share by Type (2021-2026) Table 30. Global Prostate Cancer Drugs Sales Value Share by Type (2027-2032) Table 31. Significant Companies of Clinics Table 32. Significant Companies of Hospitals Table 33. Significant Companies of Others Table 34. Global Prostate Cancer Drugs Sales Volume by Application 2021 VS 2025 VS 2032 (K Tons) Table 35. Global Prostate Cancer Drugs Sales Volume by Application (2021-2026) & (K Tons) Table 36. Global Prostate Cancer Drugs Sales Volume by Application (2027-2032) & (K Tons) Table 37. Global Prostate Cancer Drugs Sales Volume Share by Application (2021-2026) Table 38. Global Prostate Cancer Drugs Sales Volume Share by Application (2027-2032) Table 39. Global Prostate Cancer Drugs Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 40. Global Prostate Cancer Drugs Sales Value by Application (2021-2026) & (US$ Million) Table 41. Global Prostate Cancer Drugs Sales Value by Application (2027-2032) & (US$ Million) Table 42. Global Prostate Cancer Drugs Sales Value Share by Application (2021-2026) Table 43. Global Prostate Cancer Drugs Sales Value Share by Application (2027-2032) Table 44. Global Prostate Cancer Drugs Sales by Region: 2021 VS 2025 VS 2032 (K Tons) Table 45. Global Prostate Cancer Drugs Sales by Region (2021-2026) & (K Tons) Table 46. Global Prostate Cancer Drugs Sales Market Share by Region (2021-2026) Table 47. Global Prostate Cancer Drugs Sales by Region (2027-2032) & (K Tons) Table 48. Global Prostate Cancer Drugs Sales Market Share by Region (2027-2032) Table 49. Global Prostate Cancer Drugs Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 50. Global Prostate Cancer Drugs Sales Value by Region (2021-2026) & (US$ Million) Table 51. Global Prostate Cancer Drugs Sales Value Share by Region (2021-2026) Table 52. Global Prostate Cancer Drugs Sales Value by Region (2027-2032) & (US$ Million) Table 53. Global Prostate Cancer Drugs Sales Value Share by Region (2027-2032) Table 54. Global Prostate Cancer Drugs Market Average Price (US$/Ton) by Region (2021-2026) Table 55. Global Prostate Cancer Drugs Market Average Price (US$/Ton) by Region (2027-2032) Table 56. Global Prostate Cancer Drugs Sales by Country: 2021 VS 2025 VS 2032 (K Tons) Table 57. Global Prostate Cancer Drugs Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 58. Global Prostate Cancer Drugs Sales by Country (2021-2026) & (K Tons) Table 59. Global Prostate Cancer Drugs Sales Market Share by Country (2021-2026) Table 60. Global Prostate Cancer Drugs Sales by Country (2027-2032) & (K Tons) Table 61. Global Prostate Cancer Drugs Sales Market Share by Country (2027-2032) Table 62. Global Prostate Cancer Drugs Sales Value by Country (2021-2026) & (US$ Million) Table 63. Global Prostate Cancer Drugs Sales Value Market Share by Country (2021-2026) Table 64. Global Prostate Cancer Drugs Sales Value by Country (2027-2032) & (US$ Million) Table 65. Global Prostate Cancer Drugs Sales Value Market Share by Country (2027-2032) Table 66. Takeda Pharmaceuticals Company Information Table 67. Takeda Pharmaceuticals Business Overview Table 68. Takeda Pharmaceuticals Prostate Cancer Drugs Sales (K Tons), Value (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 69. Takeda Pharmaceuticals Prostate Cancer Drugs Product Portfolio Table 70. Takeda Pharmaceuticals Recent Development Table 71. Teva Pharmaceutical Company Information Table 72. Teva Pharmaceutical Business Overview Table 73. Teva Pharmaceutical Prostate Cancer Drugs Sales (K Tons), Value (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 74. Teva Pharmaceutical Prostate Cancer Drugs Product Portfolio Table 75. Teva Pharmaceutical Recent Development Table 76. Sanofi Company Information Table 77. Sanofi Business Overview Table 78. Sanofi Prostate Cancer Drugs Sales (K Tons), Value (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 79. Sanofi Prostate Cancer Drugs Product Portfolio Table 80. Sanofi Recent Development Table 81. Johnson & Johnson Company Information Table 82. Johnson & Johnson Business Overview Table 83. Johnson & Johnson Prostate Cancer Drugs Sales (K Tons), Value (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 84. Johnson & Johnson Prostate Cancer Drugs Product Portfolio Table 85. Johnson & Johnson Recent Development Table 86. Novartis Company Information Table 87. Novartis Business Overview Table 88. Novartis Prostate Cancer Drugs Sales (K Tons), Value (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 89. Novartis Prostate Cancer Drugs Product Portfolio Table 90. Novartis Recent Development Table 91. Merck Group Company Information Table 92. Merck Group Business Overview Table 93. Merck Group Prostate Cancer Drugs Sales (K Tons), Value (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 94. Merck Group Prostate Cancer Drugs Product Portfolio Table 95. Merck Group Recent Development Table 96. GlaxoSmithKline Company Information Table 97. GlaxoSmithKline Business Overview Table 98. GlaxoSmithKline Prostate Cancer Drugs Sales (K Tons), Value (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 99. GlaxoSmithKline Prostate Cancer Drugs Product Portfolio Table 100. GlaxoSmithKline Recent Development Table 101. Amgen Company Information Table 102. Amgen Business Overview Table 103. Amgen Prostate Cancer Drugs Sales (K Tons), Value (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 104. Amgen Prostate Cancer Drugs Product Portfolio Table 105. Amgen Recent Development Table 106. AbbVie Company Information Table 107. AbbVie Business Overview Table 108. AbbVie Prostate Cancer Drugs Sales (K Tons), Value (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 109. AbbVie Prostate Cancer Drugs Product Portfolio Table 110. AbbVie Recent Development Table 111. Tokai Pharmaceuticals Company Information Table 112. Tokai Pharmaceuticals Business Overview Table 113. Tokai Pharmaceuticals Prostate Cancer Drugs Sales (K Tons), Value (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 114. Tokai Pharmaceuticals Prostate Cancer Drugs Product Portfolio Table 115. Tokai Pharmaceuticals Recent Development Table 116. Spectrum Pharmaceuticals Company Information Table 117. Spectrum Pharmaceuticals Business Overview Table 118. Spectrum Pharmaceuticals Prostate Cancer Drugs Sales (K Tons), Value (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 119. Spectrum Pharmaceuticals Prostate Cancer Drugs Product Portfolio Table 120. Spectrum Pharmaceuticals Recent Development Table 121. Northwest Biotherapeutics Company Information Table 122. Northwest Biotherapeutics Business Overview Table 123. Northwest Biotherapeutics Prostate Cancer Drugs Sales (K Tons), Value (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 124. Northwest Biotherapeutics Prostate Cancer Drugs Product Portfolio Table 125. Northwest Biotherapeutics Recent Development Table 126. Janssen Pharmaceuticals Company Information Table 127. Janssen Pharmaceuticals Business Overview Table 128. Janssen Pharmaceuticals Prostate Cancer Drugs Sales (K Tons), Value (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 129. Janssen Pharmaceuticals Prostate Cancer Drugs Product Portfolio Table 130. Janssen Pharmaceuticals Recent Development Table 131. Foresee Pharmaceuticals Company Information Table 132. Foresee Pharmaceuticals Business Overview Table 133. Foresee Pharmaceuticals Prostate Cancer Drugs Sales (K Tons), Value (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 134. Foresee Pharmaceuticals Prostate Cancer Drugs Product Portfolio Table 135. Foresee Pharmaceuticals Recent Development Table 136. Ferring Pharmaceutical Company Information Table 137. Ferring Pharmaceutical Business Overview Table 138. Ferring Pharmaceutical Prostate Cancer Drugs Sales (K Tons), Value (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 139. Ferring Pharmaceutical Prostate Cancer Drugs Product Portfolio Table 140. Ferring Pharmaceutical Recent Development Table 141. Endo Pharmaceuticals Company Information Table 142. Endo Pharmaceuticals Business Overview Table 143. Endo Pharmaceuticals Prostate Cancer Drugs Sales (K Tons), Value (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 144. Endo Pharmaceuticals Prostate Cancer Drugs Product Portfolio Table 145. Endo Pharmaceuticals Recent Development Table 146. Boehringer Ingelheim Company Information Table 147. Boehringer Ingelheim Business Overview Table 148. Boehringer Ingelheim Prostate Cancer Drugs Sales (K Tons), Value (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 149. Boehringer Ingelheim Prostate Cancer Drugs Product Portfolio Table 150. Boehringer Ingelheim Recent Development Table 151. BMS Company Information Table 152. BMS Business Overview Table 153. BMS Prostate Cancer Drugs Sales (K Tons), Value (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 154. BMS Prostate Cancer Drugs Product Portfolio Table 155. BMS Recent Development Table 156. Bayer HealthCare Company Information Table 157. Bayer HealthCare Business Overview Table 158. Bayer HealthCare Prostate Cancer Drugs Sales (K Tons), Value (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 159. Bayer HealthCare Prostate Cancer Drugs Product Portfolio Table 160. Bayer HealthCare Recent Development Table 161. Astra Zeneca Company Information Table 162. Astra Zeneca Business Overview Table 163. Astra Zeneca Prostate Cancer Drugs Sales (K Tons), Value (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 164. Astra Zeneca Prostate Cancer Drugs Product Portfolio Table 165. Astra Zeneca Recent Development Table 166. Astellas Pharma Company Information Table 167. Astellas Pharma Business Overview Table 168. Astellas Pharma Prostate Cancer Drugs Sales (K Tons), Value (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 169. Astellas Pharma Prostate Cancer Drugs Product Portfolio Table 170. Astellas Pharma Recent Development Table 171. Key Raw Materials Table 172. Raw Materials Key Suppliers Table 173. Prostate Cancer Drugs Distributors List Table 174. Prostate Cancer Drugs Customers List Table 175. Research Programs/Design for This Report Table 176. Authors List of This Report Table 177. Secondary Sources Table 178. Primary Sources List of Figures Figure 1. Prostate Cancer Drugs Product Image Figure 2. Global Prostate Cancer Drugs Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Prostate Cancer Drugs Sales Value (2021-2032) & (US$ Million) Figure 4. Global Prostate Cancer Drugs Sales (2021-2032) & (K Tons) Figure 5. Global Prostate Cancer Drugs Sales Average Price (US$/Ton) & (2021-2032) Figure 6. Global Prostate Cancer Drugs Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Targeted Therapy Image Figure 10. Chemotherapy Image Figure 11. Hormonal Therapy Image Figure 12. Immunotherapy Image Figure 13. Global Prostate Cancer Drugs Sales Volume by Type (2021 VS 2025 VS 2032) & (K Tons) Figure 14. Global Prostate Cancer Drugs Sales Volume Share 2021 VS 2025 VS 2032 Figure 15. Global Prostate Cancer Drugs Sales Volume Share by Type (2021-2032) Figure 16. Global Prostate Cancer Drugs Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 17. Global Prostate Cancer Drugs Sales Value Share 2021 VS 2025 VS 2032 Figure 18. Global Prostate Cancer Drugs Sales Value Share by Type (2021-2032) Figure 19. Clinics Image Figure 20. Hospitals Image Figure 21. Others Image Figure 22. Global Prostate Cancer Drugs Sales Volume by Application (2021 VS 2025 VS 2032) & (K Tons) Figure 23. Global Prostate Cancer Drugs Sales Volume Share 2021 VS 2025 VS 2032 Figure 24. Global Prostate Cancer Drugs Sales Volume Share by Application (2021-2032) Figure 25. Global Prostate Cancer Drugs Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 26. Global Prostate Cancer Drugs Sales Value Share 2021 VS 2025 VS 2032 Figure 27. Global Prostate Cancer Drugs Sales Value Share by Application (2021-2032) Figure 28. Global Prostate Cancer Drugs Sales by Region: 2021 VS 2025 VS 2032 (K Tons) Figure 29. Global Prostate Cancer Drugs Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 30. Global Prostate Cancer Drugs Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 31. Global Prostate Cancer Drugs Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 32. North America Prostate Cancer Drugs Sales Value (2021-2032) & (US$ Million) Figure 33. North America Prostate Cancer Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 34. Europe Prostate Cancer Drugs Sales Value (2021-2032) & (US$ Million) Figure 35. Europe Prostate Cancer Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 36. Asia-Pacific Prostate Cancer Drugs Sales Value (2021-2032) & (US$ Million) Figure 37. Asia-Pacific Prostate Cancer Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 38. South America Prostate Cancer Drugs Sales Value (2021-2032) & (US$ Million) Figure 39. South America Prostate Cancer Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 40. Middle East & Africa Prostate Cancer Drugs Sales Value (2021-2032) & (US$ Million) Figure 41. Middle East & Africa Prostate Cancer Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 42. USA Prostate Cancer Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 43. USA Prostate Cancer Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 44. USA Prostate Cancer Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 45. Canada Prostate Cancer Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 46. Canada Prostate Cancer Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 47. Canada Prostate Cancer Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 48. Mexico Prostate Cancer Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 49. Mexico Prostate Cancer Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 50. Mexico Prostate Cancer Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 51. Germany Prostate Cancer Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 52. Germany Prostate Cancer Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 53. Germany Prostate Cancer Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 54. France Prostate Cancer Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 55. France Prostate Cancer Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 56. France Prostate Cancer Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 57. U.K. Prostate Cancer Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 58. U.K. Prostate Cancer Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 59. U.K. Prostate Cancer Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 60. Italy Prostate Cancer Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 61. Italy Prostate Cancer Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 62. Italy Prostate Cancer Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 63. Spain Prostate Cancer Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 64. Spain Prostate Cancer Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 65. Spain Prostate Cancer Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 66. Russia Prostate Cancer Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 67. Russia Prostate Cancer Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 68. Russia Prostate Cancer Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 69. Netherlands Prostate Cancer Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 70. Netherlands Prostate Cancer Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 71. Netherlands Prostate Cancer Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 72. Nordic Countries Prostate Cancer Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 73. Nordic Countries Prostate Cancer Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 74. Nordic Countries Prostate Cancer Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 75. China Prostate Cancer Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 76. China Prostate Cancer Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 77. China Prostate Cancer Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 78. Japan Prostate Cancer Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 79. Japan Prostate Cancer Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 80. Japan Prostate Cancer Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 81. South Korea Prostate Cancer Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 82. South Korea Prostate Cancer Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 83. South Korea Prostate Cancer Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 84. India Prostate Cancer Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 85. India Prostate Cancer Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 86. India Prostate Cancer Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 87. Australia Prostate Cancer Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 88. Australia Prostate Cancer Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 89. Australia Prostate Cancer Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 90. Southeast Asia Prostate Cancer Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 91. Southeast Asia Prostate Cancer Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 92. Southeast Asia Prostate Cancer Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 93. Brazil Prostate Cancer Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 94. Brazil Prostate Cancer Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 95. Brazil Prostate Cancer Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 96. Argentina Prostate Cancer Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 97. Argentina Prostate Cancer Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 98. Argentina Prostate Cancer Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 99. Chile Prostate Cancer Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 100. Chile Prostate Cancer Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 101. Chile Prostate Cancer Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 102. Colombia Prostate Cancer Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 103. Colombia Prostate Cancer Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 104. Colombia Prostate Cancer Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 105. Peru Prostate Cancer Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 106. Peru Prostate Cancer Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 107. Peru Prostate Cancer Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 108. Saudi Arabia Prostate Cancer Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 109. Saudi Arabia Prostate Cancer Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 110. Saudi Arabia Prostate Cancer Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 111. Israel Prostate Cancer Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 112. Israel Arabia Prostate Cancer Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 113. Israel Arabia Prostate Cancer Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 114. UAE Prostate Cancer Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 115. UAE Prostate Cancer Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 116. UAE Prostate Cancer Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 117. Turkey Prostate Cancer Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 118. Turkey Prostate Cancer Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 119. Turkey Prostate Cancer Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 120. Iran Prostate Cancer Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 121. Iran Prostate Cancer Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 122. Iran Prostate Cancer Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 123. Egypt Prostate Cancer Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 124. Egypt Prostate Cancer Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 125. Egypt Prostate Cancer Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 126. Prostate Cancer Drugs Value Chain Figure 127. Manufacturing Cost Structure Figure 128. Prostate Cancer Drugs Sales Mode & Process Figure 129. Direct Comparison with Distribution Share Figure 130. Distributors Profiles Figure 131. Years Considered Figure 132. Research Process Figure 133. Key Executives Interviewed

Scope & coverage.

Types
  • Targeted Therapy
  • Chemotherapy
  • Hormonal Therapy
  • Immunotherapy
Applications
  • Clinics
  • Hospitals
  • Others
Companies covered
  • Takeda Pharmaceuticals
  • Teva Pharmaceutical
  • Sanofi
  • Johnson & Johnson
  • Novartis
  • Merck Group
  • GlaxoSmithKline
  • Amgen
  • AbbVie
  • Tokai Pharmaceuticals
  • Spectrum Pharmaceuticals
  • Northwest Biotherapeutics
  • Janssen Pharmaceuticals
  • Foresee Pharmaceuticals
  • Ferring Pharmaceutical
  • Endo Pharmaceuticals
  • Boehringer Ingelheim
  • BMS
  • Bayer HealthCare
  • Astra Zeneca
  • Astellas Pharma

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Prostate Cancer Drugs Sales Value (2021-2032)
  4. 1.2.2 Global Prostate Cancer Drugs Sales Volume (2021-2032)
  5. 1.2.3 Global Prostate Cancer Drugs Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Prostate Cancer Drugs Market Dynamics
  1. 2.1 Prostate Cancer Drugs Industry Trends
  2. 2.2 Prostate Cancer Drugs Industry Drivers
  3. 2.3 Prostate Cancer Drugs Industry Opportunities and Challenges
  4. 2.4 Prostate Cancer Drugs Industry Restraints
3 Prostate Cancer Drugs Market by Company
  1. 3.1 Global Prostate Cancer Drugs Company Revenue Ranking in 2025
  2. 3.2 Global Prostate Cancer Drugs Revenue by Company (2021-2026)
  3. 3.3 Global Prostate Cancer Drugs Sales Volume by Company (2021-2026)
  4. 3.4 Global Prostate Cancer Drugs Average Price by Company (2021-2026)
  5. 3.5 Global Prostate Cancer Drugs Company Ranking (2024-2026)
  6. 3.6 Global Prostate Cancer Drugs Company Manufacturing Base and Headquarters
  7. 3.7 Global Prostate Cancer Drugs Company Product Type and Application
  8. 3.8 Global Prostate Cancer Drugs Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Prostate Cancer Drugs Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Prostate Cancer Drugs Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Prostate Cancer Drugs Market by Type
  1. 4.1 Prostate Cancer Drugs Type Introduction
  2. 4.1.1 Targeted Therapy
  3. 4.1.2 Chemotherapy
  4. 4.1.3 Hormonal Therapy
  5. 4.1.4 Immunotherapy
  6. 4.2 Global Prostate Cancer Drugs Sales Volume by Type
  7. 4.2.1 Global Prostate Cancer Drugs Sales Volume by Type (2021 VS 2025 VS 2032)
  8. 4.2.2 Global Prostate Cancer Drugs Sales Volume by Type (2021-2032)
  9. 4.2.3 Global Prostate Cancer Drugs Sales Volume Share by Type (2021-2032)
  10. 4.3 Global Prostate Cancer Drugs Sales Value by Type
  11. 4.3.1 Global Prostate Cancer Drugs Sales Value by Type (2021 VS 2025 VS 2032)
  12. 4.3.2 Global Prostate Cancer Drugs Sales Value by Type (2021-2032)
  13. 4.3.3 Global Prostate Cancer Drugs Sales Value Share by Type (2021-2032)
5 Prostate Cancer Drugs Market by Application
  1. 5.1 Prostate Cancer Drugs Application Introduction
  2. 5.1.1 Clinics
  3. 5.1.2 Hospitals
  4. 5.1.3 Others
  5. 5.2 Global Prostate Cancer Drugs Sales Volume by Application
  6. 5.2.1 Global Prostate Cancer Drugs Sales Volume by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Prostate Cancer Drugs Sales Volume by Application (2021-2032)
  8. 5.2.3 Global Prostate Cancer Drugs Sales Volume Share by Application (2021-2032)
  9. 5.3 Global Prostate Cancer Drugs Sales Value by Application
  10. 5.3.1 Global Prostate Cancer Drugs Sales Value by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Prostate Cancer Drugs Sales Value by Application (2021-2032)
  12. 5.3.3 Global Prostate Cancer Drugs Sales Value Share by Application (2021-2032)
6 Prostate Cancer Drugs Regional Sales and Value Analysis
  1. 6.1 Global Prostate Cancer Drugs Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Prostate Cancer Drugs Sales by Region (2021-2032)
  3. 6.2.1 Global Prostate Cancer Drugs Sales by Region: 2021-2026
  4. 6.2.2 Global Prostate Cancer Drugs Sales by Region (2027-2032)
  5. 6.3 Global Prostate Cancer Drugs Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Prostate Cancer Drugs Sales Value by Region (2021-2032)
  7. 6.4.1 Global Prostate Cancer Drugs Sales Value by Region: 2021-2026
  8. 6.4.2 Global Prostate Cancer Drugs Sales Value by Region (2027-2032)
  9. 6.5 Global Prostate Cancer Drugs Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Prostate Cancer Drugs Sales Value (2021-2032)
  12. 6.6.2 North America Prostate Cancer Drugs Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Prostate Cancer Drugs Sales Value (2021-2032)
  15. 6.7.2 Europe Prostate Cancer Drugs Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Prostate Cancer Drugs Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Prostate Cancer Drugs Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Prostate Cancer Drugs Sales Value (2021-2032)
  21. 6.9.2 South America Prostate Cancer Drugs Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Prostate Cancer Drugs Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Prostate Cancer Drugs Sales Value Share by Country, 2025 VS 2032
7 Prostate Cancer Drugs Country-level Sales and Value Analysis
  1. 7.1 Global Prostate Cancer Drugs Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Prostate Cancer Drugs Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Prostate Cancer Drugs Sales by Country (2021-2032)
  4. 7.3.1 Global Prostate Cancer Drugs Sales by Country (2021-2026)
  5. 7.3.2 Global Prostate Cancer Drugs Sales by Country (2027-2032)
  6. 7.4 Global Prostate Cancer Drugs Sales Value by Country (2021-2032)
  7. 7.4.1 Global Prostate Cancer Drugs Sales Value by Country (2021-2026)
  8. 7.4.2 Global Prostate Cancer Drugs Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Prostate Cancer Drugs Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Prostate Cancer Drugs Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Prostate Cancer Drugs Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Prostate Cancer Drugs Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Prostate Cancer Drugs Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Prostate Cancer Drugs Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Prostate Cancer Drugs Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Prostate Cancer Drugs Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Prostate Cancer Drugs Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Prostate Cancer Drugs Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Prostate Cancer Drugs Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Prostate Cancer Drugs Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Prostate Cancer Drugs Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Prostate Cancer Drugs Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Prostate Cancer Drugs Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Prostate Cancer Drugs Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Prostate Cancer Drugs Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Prostate Cancer Drugs Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Prostate Cancer Drugs Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Prostate Cancer Drugs Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Prostate Cancer Drugs Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Prostate Cancer Drugs Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Prostate Cancer Drugs Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Prostate Cancer Drugs Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Prostate Cancer Drugs Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Prostate Cancer Drugs Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Prostate Cancer Drugs Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Prostate Cancer Drugs Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Prostate Cancer Drugs Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Prostate Cancer Drugs Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Prostate Cancer Drugs Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Prostate Cancer Drugs Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Prostate Cancer Drugs Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Prostate Cancer Drugs Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Prostate Cancer Drugs Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Prostate Cancer Drugs Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Prostate Cancer Drugs Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Prostate Cancer Drugs Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Prostate Cancer Drugs Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Prostate Cancer Drugs Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Prostate Cancer Drugs Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Prostate Cancer Drugs Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Prostate Cancer Drugs Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Prostate Cancer Drugs Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Prostate Cancer Drugs Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Prostate Cancer Drugs Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Prostate Cancer Drugs Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Prostate Cancer Drugs Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Prostate Cancer Drugs Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Prostate Cancer Drugs Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Prostate Cancer Drugs Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Prostate Cancer Drugs Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Prostate Cancer Drugs Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Prostate Cancer Drugs Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Prostate Cancer Drugs Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Prostate Cancer Drugs Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Prostate Cancer Drugs Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Prostate Cancer Drugs Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Prostate Cancer Drugs Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Prostate Cancer Drugs Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Prostate Cancer Drugs Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Prostate Cancer Drugs Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Prostate Cancer Drugs Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Prostate Cancer Drugs Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Prostate Cancer Drugs Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Prostate Cancer Drugs Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Prostate Cancer Drugs Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Prostate Cancer Drugs Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Prostate Cancer Drugs Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Prostate Cancer Drugs Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Prostate Cancer Drugs Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Prostate Cancer Drugs Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Prostate Cancer Drugs Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Prostate Cancer Drugs Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Prostate Cancer Drugs Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Prostate Cancer Drugs Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Prostate Cancer Drugs Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Prostate Cancer Drugs Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Prostate Cancer Drugs Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Prostate Cancer Drugs Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Prostate Cancer Drugs Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Prostate Cancer Drugs Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Prostate Cancer Drugs Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Prostate Cancer Drugs Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Takeda Pharmaceuticals
  2. 8.1.1 Takeda Pharmaceuticals Company Information
  3. 8.1.2 Takeda Pharmaceuticals Business Overview
  4. 8.1.3 Takeda Pharmaceuticals Prostate Cancer Drugs Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Takeda Pharmaceuticals Prostate Cancer Drugs Product Portfolio
  6. 8.1.5 Takeda Pharmaceuticals Recent Developments
  7. 8.2 Teva Pharmaceutical
  8. 8.2.1 Teva Pharmaceutical Company Information
  9. 8.2.2 Teva Pharmaceutical Business Overview
  10. 8.2.3 Teva Pharmaceutical Prostate Cancer Drugs Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Teva Pharmaceutical Prostate Cancer Drugs Product Portfolio
  12. 8.2.5 Teva Pharmaceutical Recent Developments
  13. 8.3 Sanofi
  14. 8.3.1 Sanofi Company Information
  15. 8.3.2 Sanofi Business Overview
  16. 8.3.3 Sanofi Prostate Cancer Drugs Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Sanofi Prostate Cancer Drugs Product Portfolio
  18. 8.3.5 Sanofi Recent Developments
  19. 8.4 Johnson & Johnson
  20. 8.4.1 Johnson & Johnson Company Information
  21. 8.4.2 Johnson & Johnson Business Overview
  22. 8.4.3 Johnson & Johnson Prostate Cancer Drugs Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Johnson & Johnson Prostate Cancer Drugs Product Portfolio
  24. 8.4.5 Johnson & Johnson Recent Developments
  25. 8.5 Novartis
  26. 8.5.1 Novartis Company Information
  27. 8.5.2 Novartis Business Overview
  28. 8.5.3 Novartis Prostate Cancer Drugs Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Novartis Prostate Cancer Drugs Product Portfolio
  30. 8.5.5 Novartis Recent Developments
  31. 8.6 Merck Group
  32. 8.6.1 Merck Group Company Information
  33. 8.6.2 Merck Group Business Overview
  34. 8.6.3 Merck Group Prostate Cancer Drugs Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 Merck Group Prostate Cancer Drugs Product Portfolio
  36. 8.6.5 Merck Group Recent Developments
  37. 8.7 GlaxoSmithKline
  38. 8.7.1 GlaxoSmithKline Company Information
  39. 8.7.2 GlaxoSmithKline Business Overview
  40. 8.7.3 GlaxoSmithKline Prostate Cancer Drugs Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 GlaxoSmithKline Prostate Cancer Drugs Product Portfolio
  42. 8.7.5 GlaxoSmithKline Recent Developments
  43. 8.8 Amgen
  44. 8.8.1 Amgen Company Information
  45. 8.8.2 Amgen Business Overview
  46. 8.8.3 Amgen Prostate Cancer Drugs Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 Amgen Prostate Cancer Drugs Product Portfolio
  48. 8.8.5 Amgen Recent Developments
  49. 8.9 AbbVie
  50. 8.9.1 AbbVie Company Information
  51. 8.9.2 AbbVie Business Overview
  52. 8.9.3 AbbVie Prostate Cancer Drugs Sales, Value and Gross Margin (2021-2026)
  53. 8.9.4 AbbVie Prostate Cancer Drugs Product Portfolio
  54. 8.9.5 AbbVie Recent Developments
  55. 8.10 Tokai Pharmaceuticals
  56. 8.10.1 Tokai Pharmaceuticals Company Information
  57. 8.10.2 Tokai Pharmaceuticals Business Overview
  58. 8.10.3 Tokai Pharmaceuticals Prostate Cancer Drugs Sales, Value and Gross Margin (2021-2026)
  59. 8.10.4 Tokai Pharmaceuticals Prostate Cancer Drugs Product Portfolio
  60. 8.10.5 Tokai Pharmaceuticals Recent Developments
  61. 8.11 Spectrum Pharmaceuticals
  62. 8.11.1 Spectrum Pharmaceuticals Company Information
  63. 8.11.2 Spectrum Pharmaceuticals Business Overview
  64. 8.11.3 Spectrum Pharmaceuticals Prostate Cancer Drugs Sales, Value and Gross Margin (2021-2026)
  65. 8.11.4 Spectrum Pharmaceuticals Prostate Cancer Drugs Product Portfolio
  66. 8.11.5 Spectrum Pharmaceuticals Recent Developments
  67. 8.12 Northwest Biotherapeutics
  68. 8.12.1 Northwest Biotherapeutics Company Information
  69. 8.12.2 Northwest Biotherapeutics Business Overview
  70. 8.12.3 Northwest Biotherapeutics Prostate Cancer Drugs Sales, Value and Gross Margin (2021-2026)
  71. 8.12.4 Northwest Biotherapeutics Prostate Cancer Drugs Product Portfolio
  72. 8.12.5 Northwest Biotherapeutics Recent Developments
  73. 8.13 Janssen Pharmaceuticals
  74. 8.13.1 Janssen Pharmaceuticals Company Information
  75. 8.13.2 Janssen Pharmaceuticals Business Overview
  76. 8.13.3 Janssen Pharmaceuticals Prostate Cancer Drugs Sales, Value and Gross Margin (2021-2026)
  77. 8.13.4 Janssen Pharmaceuticals Prostate Cancer Drugs Product Portfolio
  78. 8.13.5 Janssen Pharmaceuticals Recent Developments
  79. 8.14 Foresee Pharmaceuticals
  80. 8.14.1 Foresee Pharmaceuticals Company Information
  81. 8.14.2 Foresee Pharmaceuticals Business Overview
  82. 8.14.3 Foresee Pharmaceuticals Prostate Cancer Drugs Sales, Value and Gross Margin (2021-2026)
  83. 8.14.4 Foresee Pharmaceuticals Prostate Cancer Drugs Product Portfolio
  84. 8.14.5 Foresee Pharmaceuticals Recent Developments
  85. 8.15 Ferring Pharmaceutical
  86. 8.15.1 Ferring Pharmaceutical Company Information
  87. 8.15.2 Ferring Pharmaceutical Business Overview
  88. 8.15.3 Ferring Pharmaceutical Prostate Cancer Drugs Sales, Value and Gross Margin (2021-2026)
  89. 8.15.4 Ferring Pharmaceutical Prostate Cancer Drugs Product Portfolio
  90. 8.15.5 Ferring Pharmaceutical Recent Developments
  91. 8.16 Endo Pharmaceuticals
  92. 8.16.1 Endo Pharmaceuticals Company Information
  93. 8.16.2 Endo Pharmaceuticals Business Overview
  94. 8.16.3 Endo Pharmaceuticals Prostate Cancer Drugs Sales, Value and Gross Margin (2021-2026)
  95. 8.16.4 Endo Pharmaceuticals Prostate Cancer Drugs Product Portfolio
  96. 8.16.5 Endo Pharmaceuticals Recent Developments
  97. 8.17 Boehringer Ingelheim
  98. 8.17.1 Boehringer Ingelheim Company Information
  99. 8.17.2 Boehringer Ingelheim Business Overview
  100. 8.17.3 Boehringer Ingelheim Prostate Cancer Drugs Sales, Value and Gross Margin (2021-2026)
  101. 8.17.4 Boehringer Ingelheim Prostate Cancer Drugs Product Portfolio
  102. 8.17.5 Boehringer Ingelheim Recent Developments
  103. 8.18 BMS
  104. 8.18.1 BMS Company Information
  105. 8.18.2 BMS Business Overview
  106. 8.18.3 BMS Prostate Cancer Drugs Sales, Value and Gross Margin (2021-2026)
  107. 8.18.4 BMS Prostate Cancer Drugs Product Portfolio
  108. 8.18.5 BMS Recent Developments
  109. 8.19 Bayer HealthCare
  110. 8.19.1 Bayer HealthCare Company Information
  111. 8.19.2 Bayer HealthCare Business Overview
  112. 8.19.3 Bayer HealthCare Prostate Cancer Drugs Sales, Value and Gross Margin (2021-2026)
  113. 8.19.4 Bayer HealthCare Prostate Cancer Drugs Product Portfolio
  114. 8.19.5 Bayer HealthCare Recent Developments
  115. 8.20 Astra Zeneca
  116. 8.20.1 Astra Zeneca Company Information
  117. 8.20.2 Astra Zeneca Business Overview
  118. 8.20.3 Astra Zeneca Prostate Cancer Drugs Sales, Value and Gross Margin (2021-2026)
  119. 8.20.4 Astra Zeneca Prostate Cancer Drugs Product Portfolio
  120. 8.20.5 Astra Zeneca Recent Developments
  121. 8.21 Astellas Pharma
  122. 8.21.1 Astellas Pharma Company Information
  123. 8.21.2 Astellas Pharma Business Overview
  124. 8.21.3 Astellas Pharma Prostate Cancer Drugs Sales, Value and Gross Margin (2021-2026)
  125. 8.21.4 Astellas Pharma Prostate Cancer Drugs Product Portfolio
  126. 8.21.5 Astellas Pharma Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Prostate Cancer Drugs Value Chain Analysis
  2. 9.1.1 Prostate Cancer Drugs Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Prostate Cancer Drugs Sales Mode & Process
  6. 9.2 Prostate Cancer Drugs Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Prostate Cancer Drugs Distributors
  9. 9.2.3 Prostate Cancer Drugs Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst